Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Advisory Council January 2018 Meeting Presentation: Research Subcommittee Agenda

Friday, January 26, 2018

Printer Friendly Version in PDF Format (3 PDF pages)


Research Subcommittee Agenda: The Journey from Targets to Treatments

Brad Hyman and Allan Levey, Co-chairs

National Alzheimer's Project Act (NAPA) and the National Plans to Address Alzheimer's Disease

  • Prevent and Effectively Treat Alzheimer's Disease by 2025.
  • Optimize Care Quality and Efficiency.
  • Expand Supports for People with Alzheimer's Disease and Their Families.
  • Enhance Public Awareness and Engagement.
  • Track Progress and Drive Improvement.

NIH AD and ADRD Research Summits - Recommendations

  • AD 2015
    • Interdisciplinary Research to Understand the Heterogeneity and Multifactorial Etiology of Disease
    • Transforming AD Therapy Development: From Targets to Trials
    • New Strategies for Prevention
    • Innovating Disease Monitoring, Assessment and Care
    • Empowering Patients, Engaging Citizens
    • Enabling Partnerships for Open Innovation
  • ADRD 2016
    • Multiple Etiology Dementias -- Diagnosing Dementia in the 21st Century
    • Non-Governmental Organizations
    • AD/ADRD Health Disparities
    • Lewy Body Dementias
    • Frontotemporal Lobar Degeneration
    • Vascular Contributions to Cognitive Impairment and Dementia

The Progression of Alzheimer's Disease and Clinical Trials

Complicated diagram. Listen to session video for explanation.
Modified from Jack et al., Lancet Neurol (2009)

Challenges of developing treatments for AD

  • Prevention, disease modifying, and symptomatic treatments may have substantially different therapeutic targets, and certainly require different clinical trial designs
  • Disease heterogeneity -- varied rates of progression -- make trials complicated to run with a typical trial having thousands of patients followed for 2 or more years, at a cost of hundreds of millions per trial
  • Complicated disease with potentially different "phases" -- may need a "right person, right time, right drug" approach, in analogy to chronic diseases like atherosclerosis or even cancer -- where different therapies are used to prevent illness or treat established disease
  • Recent high profile failures lead to caution in new investments

January 26, 2018 -- Advisory Council Meeting #27

The meeting was held on Friday, January 26, 2018, in Washington, DC. The Research Subcommittee took charge of this meeting's theme, focusing on the process from targets to treatments. The Council heard speakers on the preclinical pipeline, the clinical trial pipeline, and the industry perspective. The meeting also included discussion of a driver diagram to guide the Council's future work, updates and a report from the October Care Summit, and federal workgroup updates. Material available from this meeting is listed below and at

Comments and questions, or alerts to broken links, should be sent to


General Information




Presentation Slides



  • Updates since October meeting -- [Video]

  • NAPA Driver Diagram -- [Video]

  • Federal Updates -- [Video]

  • Public Comments -- [Video]

  • Research Subcommittee Agenda -- [Video]

  • Care Summit Update -- [Video]